Modern drug treatment of chronic asthma
BMJ 1999; 318 doi: https://doi.org/10.1136/bmj.318.7180.380 (Published 06 February 1999) Cite this as: BMJ 1999;318:380
- Brian J Lipworth, professor of allergy and respiratory medicine (b.j.lipworth@dundee.ac.uk)
- Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY
The drug treatment of asthma has remained essentially unchanged over the past three decades in terms of the use of corticosteroid, β2 agonist, and theophylline drugs. Asthma treatment has also been improved by the widespread dissemination and implementation of management guidelines emphasising the pivotal role of first line preventative, anti-inflammatory therapy. 1 2 This article provides a brief overview of modern drug treatment for chronic asthma. It does not cover the treatment of acute asthma, which is discussed in detail elsewhere.3
Summary points
The dose of inhaled steroid should be titrated against asthmatic symptoms, peak flow, and usage of β2 agonist drugs
The safest dose of inhaled steroid is the lowest effective maintenance dose producing optimal long term control and quality of life
Adding second line anti-inflammatory controller treatment such as a leukotriene antagonist or theophylline may be an alternative to monotherapy with a high dose of inhaled steroid
If control is inadequate despite optimised anti-inflammatory treatment, it is better to add regular treatment with a long acting β2 agonist drug than a short acting one
Methods
I searched Medline and BIDS for articles published between 1977 and 1998, using appropriate index terms for each drug or class of drugs. I included key review articles and searched manually for relevant papers and abstracts in recent issues of mainstream journals on general, respiratory, and allergy medicine. This article was also based on personal, long standing, clinical and research interests in the management of allergy and asthma. Some aspects of this review will inevitably be based on personal opinion, particularly where the latest guidelines are already out of date—for example, with the emerging role of leukotriene antagonists.
The inflammatory cascade in asthma
First principles of treatment
The past decade of research has led to a greater understanding of the pathophysiology of asthma and, in particular, …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.